Advertisement


Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480

ASCO20 Virtual Scientific Program

Advertisement

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed or refractory multiple myeloma, with an overall response rate of 48%. The study is ongoing to further optimize dose and schedule (Abstract 8500).



Related Videos

Bladder Cancer
Immunotherapy

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).

Multiple Myeloma
Immunotherapy

Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease

Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma. Efficacy and safety data support a favorable clinical benefit-risk profile across the target dose range (Abstract 8503).

Prostate Cancer

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?

David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (Abstracts 5506, 5507, and 5508).

Colorectal Cancer
Immunotherapy

Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease

Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA4).

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program

Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.

Advertisement

Advertisement




Advertisement